Creative Biolabs has expanded its in vitro diagnostics (IVD) capabilities to include integrated protein and nucleic acid detection, addressing the growing need for multi-dimensional biomarker analysis in early disease diagnosis. The company now offers systematic protein-level detection services and protein biomarker detection services, alongside a novel combined nucleic acid and protein detection approach.
Proteins serve as direct mediators of physiological and pathological processes, offering a more immediate reflection of cellular activity compared to genetic testing. This makes them critical targets in diagnostics and drug development. Creative Biolabs utilizes advanced technology platforms, including ELISA, multiplex assays, mass spectrometry, and protein arrays, to provide reliable data even from limited sample volumes. A company expert emphasized that protein-level studies can track disease onset and development more rapidly than genetic testing, ensuring stable and reproducible results.
Protein biomarker detection is pivotal for early diagnosis of conditions such as cancer, neurodegenerative diseases, and infectious diseases. Creative Biolabs supports clients with established biomarker detection processes, rigorously controlling each step from sample preparation to data interpretation. The expert noted the importance of data quality and detection sensitivity, stating that the company's rigorous controls deliver reliable, high-quality data.
Recognizing that a single biomarker often fails to capture disease complexity, Creative Biolabs has developed combined nucleic acid and protein detection services. This approach allows simultaneous analysis of protein and nucleic acid signals in a single assay, saving sample volume and time while revealing cross-level molecular interactions. The combined detection enhances early disease detection and clinical assessment, with advantages already established in studies on pancreatic cancer, cardiovascular disease, and other complex conditions. The expert highlighted that integrated protein and nucleic acid biomarkers could represent the future of IVD, enabling earlier and more accurate identification of disease patterns.
Creative Biolabs, a global CRO, aims to provide responsive, modifiable, and high-value services. Whether focusing on a single protein target or multi-dimensional combined detection, the team designs experimental strategies that balance client needs with scientific rigor and practical outcomes.
